AbbVie Secures Deal with Medincell for Long-Acting Injectable Platform, Valued up to $1.9 Billion

1. AbbVie has entered into a deal with Medincell, a French biotech company, for its long-acting injectable platform.
2. The deal is valued up to $1.9 billion, with AbbVie providing Medincell an upfront payment of $35 million.
3. The agreement was announced on April 16, 2024.
4. The deal represents AbbVie's investment in long-acting injectable technology, which may offer extended therapeutic benefits for patients.

Sources:
- Endpoints
- LinkedIn posts by LucidQuest and Dr. Timos Papagatsias
- Twitter post by Nicole DeFeudis